Best Healthcare Stocks Worth Watching - November 17th

SELLAS Life Sciences Group logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Seven healthcare stocks flagged by MarketBeat for high recent dollar trading volume: SELLAS Life Sciences, Eli Lilly, UnitedHealth, Moderna, Johnson & Johnson, CVS Health, and Stryker.
  • SELLAS stood out, rising $12.20 to $19.67 on nearly 90 million shares—about 11 times its average volume. Its lead cancer immunotherapy candidate is in Phase 3 trials for acute myeloid leukemia.
  • Trading was mixed among the other names: Stryker gained $8.09, while Eli Lilly, UnitedHealth, Moderna, Johnson & Johnson, and CVS Health fell. The companies span pharmaceuticals, biotech, insurance, healthcare services, and medical technology.
  • Interested in SELLAS Life Sciences Group? Here are five stocks we like better.

SELLAS Life Sciences Group, Eli Lilly and Company, UnitedHealth Group, Moderna, Johnson & Johnson, CVS Health, and Stryker are the seven Healthcare stocks to watch today, according to MarketBeat's stock screener tool. Healthcare stocks are shares of publicly traded companies involved in the healthcare industry, such as pharmaceutical and biotech firms, medical-device makers, hospitals, and health insurers. Investors may buy them for potential growth or income, while recognizing that their performance can be influenced by factors such as regulation, medical research results, and healthcare demand. These companies had the highest dollar trading volume of any Healthcare stocks within the last several days.

SELLAS Life Sciences Group (SLS)

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.

NASDAQ:SLS traded up $12.20 during midday trading on Tuesday, reaching $19.67. 89,688,999 shares of the stock traded hands, compared to its average volume of 8,228,003. The business has a 50-day moving average of $10.90 and a two-hundred day moving average of $8.79. SELLAS Life Sciences Group has a 12-month low of $1.39 and a 12-month high of $24.89. The stock has a market capitalization of $3.97 billion, a PE ratio of -99.91 and a beta of 2.73.

Read Our Latest Research Report on SLS

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Shares of LLY traded down $16.67 during midday trading on Tuesday, hitting $1,415.00. 1,126,930 shares of the company's stock traded hands, compared to its average volume of 2,950,144. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. The stock has a market capitalization of $1.33 trillion, a price-to-earnings ratio of 45.91, a price-to-earnings-growth ratio of 1.71 and a beta of 0.40. Eli Lilly and Company has a 1 year low of $850.51 and a 1 year high of $1,475.25. The firm's fifty day moving average is $1,247.93 and its 200-day moving average is $1,112.33.

Read Our Latest Research Report on LLY

UnitedHealth Group (UNH)

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.

NYSE:UNH traded down $15.97 during mid-day trading on Tuesday, hitting $396.05. 3,610,196 shares of the company's stock traded hands, compared to its average volume of 7,142,845. The company has a fifty day moving average of $391.66 and a 200 day moving average of $366.24. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.74 and a current ratio of 0.74. UnitedHealth Group has a twelve month low of $255.96 and a twelve month high of $461.62. The company has a market capitalization of $354.87 billion, a P/E ratio of 22.63, a P/E/G ratio of 1.47 and a beta of 0.51.

Read Our Latest Research Report on UNH

Moderna (MRNA)

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Shares of MRNA stock traded down $10.30 during trading hours on Tuesday, reaching $204.97. 3,970,481 shares of the company's stock were exchanged, compared to its average volume of 12,508,618. Moderna has a 1 year low of $22.28 and a 1 year high of $280.80. The stock has a market cap of $82.93 billion, a PE ratio of -28.94 and a beta of 1.16. The company has a current ratio of 3.62, a quick ratio of 3.47 and a debt-to-equity ratio of 0.52. The stock's fifty day moving average price is $203.06 and its two-hundred day moving average price is $97.26.

Read Our Latest Research Report on MRNA

Johnson & Johnson (JNJ)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Shares of Johnson & Johnson stock traded down $2.77 during midday trading on Tuesday, hitting $279.78. The company had a trading volume of 2,204,532 shares, compared to its average volume of 7,926,807. The stock has a market cap of $673.51 billion, a price-to-earnings ratio of 42.40, a PEG ratio of 2.80 and a beta of 0.22. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. The company has a fifty day simple moving average of $267.12 and a 200 day simple moving average of $250.12. Johnson & Johnson has a 12-month low of $198.53 and a 12-month high of $290.25.

Read Our Latest Research Report on JNJ

CVS Health (CVS)

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

NYSE:CVS traded down $2.34 during trading hours on Tuesday, hitting $86.25. 6,039,727 shares of the company were exchanged, compared to its average volume of 8,618,643. The stock has a market capitalization of $110.36 billion, a price-to-earnings ratio of 10.05, a PEG ratio of 0.78 and a beta of 0.58. CVS Health has a 52-week low of $69.51 and a 52-week high of $110.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.85 and a quick ratio of 0.66. The company's 50 day moving average price is $89.48 and its 200-day moving average price is $89.16.

Read Our Latest Research Report on CVS

Stryker (SYK)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Shares of NYSE SYK traded up $8.09 during midday trading on Tuesday, reaching $318.81. The company had a trading volume of 1,521,762 shares, compared to its average volume of 2,515,933. The business's 50-day simple moving average is $292.44 and its 200 day simple moving average is $322.36. The stock has a market cap of $121.37 billion, a P/E ratio of 33.90, a P/E/G ratio of 2.14 and a beta of 0.78. Stryker has a 1 year low of $267.00 and a 1 year high of $389.33. The company has a current ratio of 2.18, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60.

Read Our Latest Research Report on SYK

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in SELLAS Life Sciences Group Right Now?

Before you consider SELLAS Life Sciences Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.

While SELLAS Life Sciences Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines